Switch theme
Sign up to access all valuation multiples
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
2014
908
LTM Revenue $137M
LTM EBITDA -$1.0B
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Roivant Sciences has a last 12-month revenue of $137M and a last 12-month EBITDA of -$1.0B.
In the most recent fiscal year, Roivant Sciences achieved revenue of $125M and an EBITDA of $4.3B.
Roivant Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Roivant Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $61.3M | $125M | XXX | XXX | XXX |
| Gross Profit | $46.3M | $48.2M | XXX | XXX | XXX |
| Gross Margin | 76% | 39% | XXX | XXX | XXX |
| EBITDA | -$1.2B | $4.3B | XXX | XXX | XXX |
| EBITDA Margin | -1922% | 3454% | XXX | XXX | XXX |
| Net Profit | -$845M | -$1.0B | XXX | XXX | XXX |
| Net Margin | -1379% | -809% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Roivant Sciences's stock price is $10.
Roivant Sciences has current market cap of $7.3B, and EV of $2.2B.
See Roivant Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $7.3B | XXX | XXX | XXX | XXX | $-0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Roivant Sciences has market cap of $7.3B and EV of $2.2B.
Roivant Sciences's trades at 16.3x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate Roivant Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Roivant Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 16.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | XXX | XXX |
| P/E | 7.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRoivant Sciences's NTM/LTM revenue growth is -81%
Roivant Sciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Roivant Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Roivant Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Roivant Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 104% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 229% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -466% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 148% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 402% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 953% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Roivant Sciences acquired XXX companies to date.
Last acquisition by Roivant Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Roivant Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Roivant Sciences founded? | Roivant Sciences was founded in 2014. |
| Where is Roivant Sciences headquartered? | Roivant Sciences is headquartered in United States of America. |
| How many employees does Roivant Sciences have? | As of today, Roivant Sciences has 908 employees. |
| Who is the CEO of Roivant Sciences? | Roivant Sciences's CEO is Mr. Matthew Gline. |
| Is Roivant Sciences publicy listed? | Yes, Roivant Sciences is a public company listed on NAS. |
| What is the stock symbol of Roivant Sciences? | Roivant Sciences trades under ROIV ticker. |
| When did Roivant Sciences go public? | Roivant Sciences went public in 2021. |
| Who are competitors of Roivant Sciences? | Similar companies to Roivant Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Roivant Sciences? | Roivant Sciences's current market cap is $7.3B |
| What is the current revenue of Roivant Sciences? | Roivant Sciences's last 12-month revenue is $137M. |
| What is the current EBITDA of Roivant Sciences? | Roivant Sciences's last 12-month EBITDA is -$1.0B. |
| What is the current EV/Revenue multiple of Roivant Sciences? | Current revenue multiple of Roivant Sciences is 16.3x. |
| What is the current EV/EBITDA multiple of Roivant Sciences? | Current EBITDA multiple of Roivant Sciences is -2.2x. |
| What is the current revenue growth of Roivant Sciences? | Roivant Sciences revenue growth between 2023 and 2024 was 104%. |
| Is Roivant Sciences profitable? | Yes, Roivant Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
